Reading Resources
The following list includes websites with comprehensive information about prurigo nodularis (PN), including up-to-date information on recent FDA-approved treatments.
Websites
| Name | Link |
|---|---|
| American Academy of Dermatology Association (AAD) | https://www.aad.org/public/diseases/a-z/prurigo-nodularis-overview |
| American Osteopathic College of Dermatology (AOCD) | https://www.aocd.org/page/PrurigoNodularis |
| National Organization for Rare Disorders (NORD) | https://rarediseases.org/rare-diseases/prurigo-nodularis/#disease-overview-main |
| US National Library of Medicine Clinical Trials | https://beta.clinicaltrials.gov/ |
| All URLs accessed on June 12, 2023. | |
Ongoing clinical trials for the treatment of prurigo nodularis
| Agent | Study link |
|---|---|
| Ruxolitinib | NCT05764161, NCT05755438 |
| Barzolvolimab | NCT06366750 |
| Nemolizumab | NCT05052983, NCT04501666, NCT04204616 |
| Apremilast | NCT03576287 |
| Vixarelimab | NCT03816891 |
| Povorcitinib | NCT06516952, NCT06516965 |
| Abrocitinib | NCT05038982 |
References
US National Library of Medicine. Clinical trials. https://beta.clinicaltrials.gov/.
